Comparative Adverse Event Profiles of Triplet Therapy Versus Docetaxel-Based Therapy in Patients with Metastatic Prostate Cancer: A Multicenter Retrospective Study - Beyond the Abstract
This research compares triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) with docetaxel-based therapy (docetaxel and ADT), focusing on adverse event (AE) profiles in patients with metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC). These insights are essential for clinicians, as they guide treatment decisions for prostate cancer patients in various disease stages.
One of the key findings of the study is the lack of significant differences in the incidence of severe neutropenia (≥ grade 3) or febrile neutropenia (FN) between patients receiving triplet therapy and those undergoing docetaxel-based therapy. This is an important result, as neutropenia and FN are well-known complications of docetaxel treatment. The absence of increased hematologic AEs with the addition of an ARSI (e.g., darolutamide) to docetaxel and ADT suggests that triplet therapy may be a viable option without exacerbating these risks. For clinicians, this finding is reassuring, as it allows for the integration of new therapeutic strategies without significantly altering the safety profile of treatment.
The study also highlights the crucial role of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in mitigating the risks of severe neutropenia and FN. Patients who received G-CSF had significantly lower odds of developing these AEs, emphasizing the importance of this supportive care measure in enhancing patient safety. The data underscores that primary prophylaxis should be considered as a routine part of treatment for prostate cancer patients undergoing docetaxel-based therapy, as it plays a pivotal role in minimizing treatment delays or dose reductions due to neutropenia.
In addition to hematologic AEs, the study also examines non-hematologic side effects, with fatigue being the most frequently reported. While fatigue was more prevalent in the mCRPC group compared to the triplet therapy group, it remained a common concern across all treatment regimens. This finding suggests that fatigue is an important factor to manage in prostate cancer therapy, and clinicians should remain vigilant in monitoring and addressing this issue. Regular clinical assessments and potential dose adjustments may help mitigate the impact of fatigue on patient quality of life during treatment.
Furthermore, the study found that the addition of darolutamide to docetaxel and ADT in triplet therapy did not result in a marked increase in adverse events. This aligns with the growing body of evidence supporting the safety of combining ARSIs with docetaxel, making triplet therapy a promising approach for mCSPC patients. Importantly, the addition of darolutamide did not exacerbate the safety concerns typically associated with docetaxel, suggesting that triplet therapy can be an effective and safe treatment option for patients in the earlier stages of prostate cancer.
Overall, this study provides a valuable real-world analysis of treatment safety and offers important clinical insights into the tolerability of triplet therapy versus docetaxel-based therapies. The results suggest that triplet therapy does not significantly alter the adverse event profile compared to docetaxel-based therapies, and the use of primary prophylaxis with G-CSF plays a critical role in reducing the incidence of severe neutropenia and FN. These findings will be valuable for clinicians in making informed treatment decisions and improving patient outcomes. Future research, including larger prospective studies with cycle-based data, will be essential to further validate these results and explore additional strategies to manage non-hematologic AEs like fatigue.
As the treatment landscape for metastatic prostate cancer continues to evolve, this study provides important evidence that can guide clinicians in balancing the efficacy and safety of combination therapies. With continued research and careful management of AEs, clinicians can better optimize treatment strategies to enhance the quality of life and survival outcomes for patients with metastatic prostate cancer.
Written by: Fumihiko Urabe, MD, PhD, Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
Reference:
Read the Abstract